The Department of Health and Human Services (HHS) Office of the Inspector General (OIG) released a report showing that biosimilar competition has led to lower costs for the Medicare Part B program and enrollees. Part B drugs are usually large, complex molecules delivered through infusions or injections in a doctor’s office. These are some of the most costly drugs and often… (McClurg, October 3, 2023) #Biosimilars